Skip to main content
Hoon Kim on Muck Rack

Hoon Kim

As seen in: Medium, Nature, Wiley Online Library, MDPI, Taylor & Francis Online, ACS Publications, Flipboard, The Journal of NeuroInterventional Surgery (JNIS), Science Magazine, Green Chemistry and

Get in touch with Hoon

Contact Hoon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Computer Science > Computer Vision and Pattern Recognition

|
By Hoon Kim
| arxiv.org
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Open in Who Shared View Duplicates (666) Issue with article?

Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study

|
By Dawon Kang, Seungwon Lee, Seungsoo Kim, Ina Jeon, Eunjin Park, Jungmin Choi, Moon-Won Yoo, Joon Seon Song, Yong-Hee Kim, Hyeong Ryul Kim, Ho June Song, Hoon Kim, Kee Don Choi, Jeong Hoon Lee, Ji Yong Ahn, Ju Hyun Shim, Danbi Lee, Jonggi Choi, Ji Kim, Sang-Yeob Kim, Dong-Jun Bae, Gi-Won Song
| Nature Verified
Abstract Neoadjuvant immunotherapy may improve long-term outcomes by activating antitumor immunity before surgery. We evaluated danburstotug (IMC-001), an anti–PD-L1 antibody, in resectable gastric cancer (GC), esophageal squamous cell carcinoma (ESCC), and hepatocellular carcinoma (HCC). In this phase II trial, patients received two cycles of danburstotug (20 mg/kg every 2 weeks) before surgery. The primary endpoint was major pathologic response (MPR, <10% viable tumor).
Open in Who Shared Issue with article?

Synthesis, biological evaluation and in silico studies of novel propargyl-tethered isatin hydrazones as monoamine oxidase inhibitors for Parkinson’s disease

|
By Hee jung Kim, Jaeyeop Lim, Mohamed abdelgawad, Mohammed M. Ghoneim, Sunil Kumar, Sandeep Kumar, Hoon Kim, Bijo Mathew, Saranya Kattil Parmbil, Mohamed Sadek Abdel-Bakky, Harish Chandra Vishwakarma
| Nature Verified
Abstract Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors.
Open in Who Shared Issue with article?
See all 88 licensed articles (91 Total)